

Dua K. Application of model independent approach on *in vitro* release of extemporaneously prepared semisolid formulations containing metronidazole with marketed silver sulfadiazine 1% cream, USP: A comparative investigation. *Bull. Pharm. Res.* 2013;3(1):1-5.

References (18):

1. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: *in vitro* characterization. *Acta Pharm.* 2003;53(2):119-25.
<http://www.ncbi.nlm.nih.gov/pubmed/14764246>
2. Benner MW, Bencon PM, James WD. Topical Antibiotics in Dermatology, 5th ed, McGraw Hill: New York, 1999; 25-7.
3. Brazilian Health Surveillance Agency (ANVISA). 2009. Flagyl label. Accessed December 15, 2009.
<http://www4.anvisa.gov.br/base/visadoc/BM/BM%5B26406-1-0%5D.PDF>
4. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. *Eur. J. Pharm. Sci.* 2001;13(2):123-33.
<http://www.ncbi.nlm.nih.gov/pubmed/11297896>
5. Dhavse VV, Amin PD. Formulation and evaluation of topical bases of ketoprofen. *East Pharm.* 1997;480:133-6.
6. Dua K, Pabreja K, Ramana MV. Aceclofenac topical dosage forms: *In vitro* and *in vivo* characterization. *Acta Pharm.* 2010;60(4):467-78.
<http://public.carnet.hr/acphee/46710.pdf>
7. Ezzedeen FW, Shihab FA, Husain EJ. Percutaneous diffusion of cefalexin, sulfamethoxazole and diphenhydramine from ointments. *Pharmazie* 1990;45(7):512-4.
<http://www.ncbi.nlm.nih.gov/pubmed/2236194>
8. FDA, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms (BP1). Centre for drug evaluation and research, Food and drug administration. 1997; Rockville, MD, P9.
<http://www.fda.gov/cder/guidance>
9. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. *Pharm. Technol.* 1996;20(6):64-74.
10. Nagia AE, Hanan ME, Gehan FB. Formulation and evaluation of meloxicam gels for topical administration. *Saudi Pharm. J.* 2006;14(3-4):155-62.
http://www.arabrepository.info/jourarticle.php?art_id=14374&jcode=J056&sourcename=Saudi+Pharmaceutical+Journal&pagenum=14

11. Pandey S, Basheer M, Roy S, Udupa N. Development and evaluation of transdermal formulations containing metronidazole and norfloxacin for the treatment of burn wound. *Indian J. Exp. Biol.* 1999;37(5):450-4.
<http://www.ncbi.nlm.nih.gov/pubmed/10492616>
12. Parikh NH , Babar A, Plakogiannis FM. Medicament release from ointment bases: II. Testosterone: *in vitro* release and effects of additives on its release. *Drug Dev. Ind. Pharm.* 1986;12(14):2493-2509.
<http://informahealthcare.com/doi/abs/10.3109/03639048609063195>
13. Perez-Marcos B, Iglesias R, Gomez-Amoza JL, Martinez-Pacheco R, Souto C, Concheiro A. Mechanical and drug-release properties of atenolol-carbomer hydrophilic matrix tablets. *J. Control. Rel.* 1991;17(3):267-76.
<http://www.sciencedirect.com/science/article/pii/0168365991901454>
14. Rajni V, Verma PRP. Diffusion study of ibuprofen from ointment bases. *Ind. J. Pharm. Sci.* 1995;57(1):1-6.
http://www.iipsonline.com/temp/IndianJPharmSci5711-252222_070022.pdf
15. Sable D, Murakawa GJ. Quinolones in Dermatology. *Clin. Dermatol.* 2003;21(1):56-63.
<http://www.ncbi.nlm.nih.gov/pubmed/12609589>
16. Sanna V, Peana AT, Moretti MD. Effect of vehicle on diclofenac sodium permeation from new topical formulations: *in vitro* and *in vivo* studies. *Curr. Drug Deliv.* 2009;6(1):93-100.
<http://www.ncbi.nlm.nih.gov/pubmed/19418961>
17. Singh S, Gajra B, Rawat M, Muthu MS. Enhanced transdermal delivery of ketoprofen from bioadhesive gels. *Pak. J. Pharm. Sci.* 2009;22(2):193-8.
<http://www.ncbi.nlm.nih.gov/pubmed/19339232>
18. World Health Organization (WHO). 2009. WHO Model Lists of Essential Medicines, 16th ed. Accessed November 20, 2009.
http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf